Literature DB >> 9322902

Durable remission after splenectomy for Waldenström's macroglobulinemia with massive splenomegaly in leukemic phase.

N Takemori1, K Hirai, R Onodera, S Kimura, M Katagiri.   

Abstract

A patient with M-proteinemia (IgM, kappa type), lymphocytosis, anemia, and massive splenomegaly, was diagnosed as having Waldenström's macroglobulinemia (WM). Since this case was refractory to chemotherapy, splenic irradiation was performed, which effectively reduced the serum IgM level, spleen size, and lymphocyte counts; however, its effect was transient. Splenectomy was then carried out. The spleen contained abundant IgM-producing lymphocytes, and after splenectomy, the serum IgM values decreased and the peripheral blood counts returned to near normal. The transient increases of serum IgM occurred during two infectious episodes postoperatively. The patient has now been in a satisfactory remission for six years after splenectomy. The removal of an IgM-producing/secreting site and release from hypersplenism may be the major mechanisms involved in achieving the durable remission after splenectomy. In individual cases of WM with massive splenomegaly, we recommend splenectomy as part of the management of this disorder.

Entities:  

Mesh:

Year:  1997        PMID: 9322902     DOI: 10.3109/10428199709051789

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

1.  Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer.

Authors:  Stavroula Sofou; Richard Enmon; Stig Palm; Barry Kappel; Pat Zanzonico; Michael R McDevitt; David A Scheinberg; George Sgouros
Journal:  J Liposome Res       Date:  2010-01-13       Impact factor: 3.648

2.  Splenic re-irradiation for waldenstrőm's macroglobulinemia.

Authors:  Zhou Wei; Yu Yanxia; Xu Ying; Wang Han; Jiang Yuhua
Journal:  Radiat Oncol       Date:  2012-04-12       Impact factor: 3.481

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.